Director Of Crinetics Pharmaceuticals Inc. (CRNX) Has Sold 6,046 Of The Company’s Shares

The stock of Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) decreased by remained unchanged at $22.49, down -0.35 percent. The last five days have seen an average of 933,840 shares of common stock traded. 23 times new highs were reached in the current year, with a gain of $8.38. The average number of shares traded over the last 20 days was 319,915, while the average volume over the last 50 days totaled 257,686.

CRNX stock appreciated 5.04% since last month. On 10/19/21, the company’s shares reached a one-month low of $18.97. The stock touched a high of $25.50 on 09/08/21, after rallying from a low of $11.61 in 52 weeks. The price of CRNX stock has risen by 59.39% or $8.38 this year, reaching a new high 23 times. Still, the stock price is down -11.80% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

There have been 47 days since Crinetics Pharmaceuticals Inc. (CRNX) last reported insider trading activity on Sep 08. On Sep 08, Director Fust Matthew K sold 6,046 shares at $25.50 each. This transaction resulted in the insider making $154,173. On Sep 07, Struthers Richard Scott sold 30,000 shares at a price of US$25.00. After the transaction, the insider now owns 90,000 shares. Director Fust Matthew K had earlier sold 5,000 shares on Jul 26 for $19.59 a share. The transaction was completed for $97,950.

For the three months ended June 29, Crinetics Pharmaceuticals Inc.’s quick ratio was 17.70, while its current ratio was 17.70, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $75.02 million and revenue of $71000.0.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. CRNX’s return on assets (ROA) during the last 12 months has been -46.60%. In the meantime, the return on equity (ROE) for the last 12 months was -50.30%. ROE has averaged -68.79 in the past year for the broader industry.

Earnings Surprise

According to Crinetics Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 29, it had $24.99 million in cash and short-term investments. It was predicted that Crinetics Pharmaceuticals Inc.’s quarterly earnings would be -$0.7, but it ended up being -$0.61, beating the consensus by -14.80%. At the end of Crinetics Pharmaceuticals Inc.’s most recent quarter ended June 29, its liabilities totaled 15.49 million, while its total debt was $4.44 million. Equity owned by shareholders amounts to $38.56 million.

Technical Picture

Here’s a quick look at Crinetics Pharmaceuticals Inc.’s (CRNX) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 70.76%, suggesting the stock is Overbought, with a 71.50% historical volatility rate.

The stochastic %K and %D were 64.75% and 54.66% respectively, while the average true range (ATR) was 1.23. Based on the 14-day stochastic reading of 75.54%, the RSI (14) reading is 63.00%. On the 9-day MACD Oscillator, the stock is at 1.32, and the 14-day reading is at 1.53.

Analyst Ratings

In its most recent analyst report, JP Morgan raised its rating on Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) to an Overweight. Prior to this, analysts firm rated the stock as a Neutral. Analysts have assigned Crinetics Pharmaceuticals Inc. (CRNX) an Buy rating. CRNX is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 5 others recommend it as a buy.

What is CRNX’s price target for the next 12 months?

The current consensus forecast for the stock is between $30.00 and $45.00, with a median target price of $37.00. In analyzing these forecasts, the average price target given by analysts for Crinetics Pharmaceuticals Inc. (CRNX) is $38.00.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam